谷氨酸通过增加药物摄入量和ROS增强了对Acinetobacter baumannii的Cefoperazone-Sulbactam活性
Shi-Wen Wang1, Zheng-Qi Shi2, Jia-Xin Zhu3
1State Key Laboratory of Bio-Control, School of Life Sciences, Southern Marine Science and Engineering Guangdong Laboratory (zhuhai), Sun Yat-Sen University, Guangzhou 510275, China.
ACS infectious diseases
|October 21, 2025
概括
结合赛福拉-苏尔巴克坦 (SCF) 与谷氨酸,显示出对抗生素耐药细菌 (如Acinetobacter baumannii) 的显著协同作用. 这种代谢重编程方法提高了抗生素的疗效,并减少了耐药性的发展.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 细菌的抗生素耐药性,特别是Acinetobacter baumannii,构成了全球健康的重大威胁.
- 需要新的治疗策略,将抗生素与代谢调节剂结合起来,以克服耐药性.
- 临床前药学动力学研究对于验证这种组合疗法至关重要.
研究的目的:
- 评估与谷氨酸相结合的赛福拉-苏尔巴克坦 (SCF) 与Acinetobacter baumannii的临床分离物相比的临床前药学动力学概况.
- 评估SCF和谷氨酸之间的协同作用,同等作用或对抗作用.
- 调查谷氨酸对SCF耐药性发展和细菌代谢的影响.
主要方法:
- 对SCF和谷氨酸的组合进行了测试,对237种Acinetobacter baumannii临床分离物进行了测试 (抗生素敏感,多药耐药,耐卡巴胺).
- 利用时间杀伤分析,细菌负载量化和小鼠感染模型来验证研究结果.
- 分析了对细菌新陈代谢,活性氧物种 (ROS) 生产,药物吸收和耐药机制的影响.
主要成果:
- 在94.51%的隔离物中,SCF-Glutamine组合表现出协同效果.
- 治疗效果在不同度和pH梯度之间保持稳定.
- 谷氨酸被证明可以减缓SCF耐药性,延长后抗生素效果,并减少突变频率.
结论:
- SCF和谷氨胺的组合显示出强大的协同活性,对抗多药耐药和耐卡巴胺的Acinetobacter baumannii.
- 谷氨酸重编程细菌新陈代谢,增强ROS的产生和药物吸收,以增加细菌的根除.
- 这种协同作用的组合代表了对抗具有挑战性的细菌感染的有希望的治疗候选者.
相关概念视频
Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
Drug Metabolism: Phase II Reactions
4.9K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.9K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
817
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
817
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
193
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
193
Gene Regulation in Microbial Communities: Quorum Sensing
517
Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
517
Pharmacokinetics: Drug–Drug Interactions
349
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
349


